Literature DB >> 10569746

Expression of sialylated or paragloboside-like lipooligosaccharides are not required for pustule formation by Haemophilus ducreyi in human volunteers.

R S Young1, K Fortney, J C Haley, A F Hood, A A Campagnari, J Wang, J A Bozue, R S Munson, S M Spinola.   

Abstract

The lipooligosaccharide (LOS) of Haemophilus ducreyi, the etiologic agent of chancroid, chemically and immunologically resembles human glycosphingolipid antigens. To test whether LOS that contains paragloboside-like structures was required for pustule formation, an isogenic mutant (35000HP-RSM2) was constructed in losB, which encodes D-glycero-D-manno-heptosyltransferase. 35000HP-RSM2 produces a truncated LOS whose major glycoform terminates in a single glucose attached to a heptose trisaccharide core and 2-keto-3-deoxyoctulosonic acid. Five human subjects were inoculated with 35000HP and 35000HP-RSM2 in a dose-response trial. For estimated delivered doses (EDDs) of >/=25 CFU, the pustule formation rates were 80% for 35000HP and 58% for 35000HP-RSM2. Preliminary data indicated that a previously described Tn916 losB mutant made a minor glycoform that does not require DD-heptose to form the terminal N-acetyllactosamine. If 35000HP-RSM2 made this glycoform, then 35000HP-RSM2 could theoretically make a sialylated glycoform. To test whether sialylated LOS was required for pustule formation, a second trial comparing an isogenic sialyltransferase mutant (35000HP-RSM203) to 35000HP was performed in five additional subjects. For EDDs of >/=25 CFU, the pustule formation rates were 30% for both 35000HP and 35000HP-RSM203. The histopathology and recovery rates of H. ducreyi from surface cultures and biopsies obtained from mutant and parent sites in both trials were similar. These results indicate that neither the expression of a major glycoform resembling paragloboside nor sialylated LOS is required for pustule formation by H. ducreyi in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569746      PMCID: PMC97038          DOI: 10.1128/IAI.67.12.6335-6340.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Haemophilus ducreyi produces a novel sialyltransferase. Identification of the sialyltransferase gene and construction of mutants deficient in the production of the sialic acid-containing glycoform of the lipooligosaccharide.

Authors:  J A Bozue; M V Tullius; J Wang; B W Gibson; R S Munson
Journal:  J Biol Chem       Date:  1999-02-12       Impact factor: 5.157

2.  Experimental human infection with Haemophilus ducreyi.

Authors:  S M Spinola; L M Wild; M A Apicella; A A Gaspari; A A Campagnari
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

3.  Lipooligosaccharide epitopes shared among gram-negative non-enteric mucosal pathogens.

Authors:  A A Campagnari; S M Spinola; A J Lesse; Y A Kwaik; R E Mandrell; M A Apicella
Journal:  Microb Pathog       Date:  1990-05       Impact factor: 3.738

4.  Cumulative experience with Haemophilus ducreyi 35000 in the human model of experimental infection.

Authors:  J A Al-Tawfiq; J Harezlak; B P Katz; S M Spinola
Journal:  Sex Transm Dis       Date:  2000-02       Impact factor: 2.830

5.  Use of pyocin to select a Haemophilus ducreyi variant defective in lipooligosaccharide biosynthesis.

Authors:  A A Campagnari; R Karalus; M Apicella; W Melaugh; A J Lesse; B W Gibson
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

6.  Mry, a trans-acting positive regulator of the M protein gene of Streptococcus pyogenes with similarity to the receptor proteins of two-component regulatory systems.

Authors:  J Perez-Casal; M G Caparon; J R Scott
Journal:  J Bacteriol       Date:  1991-04       Impact factor: 3.490

7.  Structural studies of the cell envelope lipopolysaccharides from Haemophilus ducreyi strains ITM 2665 and ITM 4747.

Authors:  E K Schweda; A C Sundström; L M Eriksson; J A Jonasson; A A Lindberg
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

8.  Role of lipooligosaccharides in experimental dermal lesions caused by Haemophilus ducreyi.

Authors:  A A Campagnari; L M Wild; G E Griffiths; R J Karalus; M A Wirth; S M Spinola
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

9.  Investigation of the structural heterogeneity of lipooligosaccharides from pathogenic Haemophilus and Neisseria species and of R-type lipopolysaccharides from Salmonella typhimurium by electrospray mass spectrometry.

Authors:  B W Gibson; W Melaugh; N J Phillips; M A Apicella; A A Campagnari; J M Griffiss
Journal:  J Bacteriol       Date:  1993-05       Impact factor: 3.490

10.  Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men.

Authors:  H Schneider; J M Griffiss; J W Boslego; P J Hitchcock; K M Zahos; M A Apicella
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  23 in total

1.  Transcription of candidate virulence genes of Haemophilus ducreyi during infection of human volunteers.

Authors:  R E Throm; S M Spinola
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 2.  Immunopathogenesis of Haemophilus ducreyi infection (chancroid).

Authors:  Stanley M Spinola; Margaret E Bauer; Robert S Munson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

3.  Sialylation of lipooligosaccharides is dispensable for the virulence of Haemophilus ducreyi in humans.

Authors:  Stanley M Spinola; Wei Li; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Barry P Katz; Robert S Munson
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

4.  Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection.

Authors:  Stanley M Spinola; Cliffton T H Bong; Andrew L Faber; Kate R Fortney; Stacy L Bennett; Carisa A Townsend; Beth E Zwickl; Steven D Billings; Tricia L Humphreys; Margaret E Bauer; Barry P Katz
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Killing of dsrA mutants of Haemophilus ducreyi by normal human serum occurs via the classical complement pathway and is initiated by immunoglobulin M binding.

Authors:  Malikah Abdullah; Igor Nepluev; Galyna Afonina; Sanjay Ram; Peter Rice; William Cade; Christopher Elkins
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  Role played by CD4+FOXP3+ regulatory T Cells in suppression of host responses to Haemophilus ducreyi during experimental infection of human volunteers.

Authors:  Wei Li; Klara Tenner-Racz; Paul Racz; Diane M Janowicz; Kate R Fortney; Barry P Katz; Stanley M Spinola
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

7.  Characterization of Haemophilus ducreyi-specific T-cell lines from lesions of experimentally infected human subjects.

Authors:  V Gelfanova; T L Humphreys; S M Spinola
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

8.  A Class I Haemophilus ducreyi Strain Containing a Class II hgbA Allele Is Partially Attenuated in Humans: Implications for HgbA Vaccine Efficacy Trials.

Authors:  Isabelle Leduc; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Sheila Ellinger; Barry P Katz; Huaiying Lin; Qunfeng Dong; Stanley M Spinola
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

9.  Carbon storage regulator A contributes to the virulence of Haemophilus ducreyi in humans by multiple mechanisms.

Authors:  Dharanesh Gangaiah; Wei Li; Kate R Fortney; Diane M Janowicz; Sheila Ellinger; Beth Zwickl; Barry P Katz; Stanley M Spinola
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

10.  Haemophilus ducreyi requires an intact flp gene cluster for virulence in humans.

Authors:  Stanley M Spinola; Kate R Fortney; Barry P Katz; Jo L Latimer; Jason R Mock; Merja Vakevainen; Eric J Hansen
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.